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In previous vaccination experiments a sub-fraction from the protective Ostertagia 
ostertagi ES-thiol fraction, essentially consisting of ‘activation-associated secreted 
proteins’ (ASPs), was used successfully to immunise calves against an Ostertagia 
challenge infection. The aim of this research project was to express the ASP1 and 
ASP2 antigens in both a modified Pichia pastoris and an insect cell expression 
system and compare the protective capacities of the recombinants with their native 
counterparts in a vaccination trial. Both the P. pastoris and insect cell expression 
systems expressed soluble dimeric forms of the ASP1 and ASP2 antigens. The 
presence of cross reactive antibodies against the native molecules in animals 
vaccinated with the recombinants suggested that the recombinant ASPs displayed 
similar immunogenic epitopes as present on the native molecules. Nevertheless, 
none of the recombinants was able to induce a significant degree of protection in 
calves. Analysis of the abomasal antibody levels showed a marked increase in 
antigen specific IgG1 levels in the protected animals from the native ASP group 
compared to all other groups, indicating a possible difference in antigen processing 
or different post translational modifications between the native and recombinant 
antigens. 
